読み込み中
Veraxa Biotech AG is a clinical-stage biopharmaceutical company specializing in next-generation antibody-based cancer therapies. [9] The company is advancing a drug discovery and development engine for ADCs and other novel antibody-based therapy concepts. [14] It was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL). [8, 14]
通常取引
$0.0318
−$0.0028 · -7.96%
Veraxa Biotech AG is a clinical-stage biopharmaceutical company specializing in next-generation antibody-based cancer therapies. [9] The company is advancing a drug discovery and development engine for ADCs and other novel antibody-based therapy concepts. [14] It was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL). [8, 14]
52週レンジ
現在 $0.0318
過去の価格は調整または遅延している場合があります。
Veraxa Biotech AG is a clinical-stage biopharmaceutical company specializing in next-generation antibody-based cancer therapies. [9] The company is advancing a drug discovery and development engine for ADCs and other novel antibody-based therapy concepts. [14] It was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL). [8, 14]
52週レンジ
現在 $0.0318
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
